A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
Abstract Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachmen...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-02-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-021-00284-w |
| _version_ | 1797641278310055936 |
|---|---|
| author | Thomas W. Geisbert Kathryn Bobb Viktoriya Borisevich Joan B. Geisbert Krystle N. Agans Robert W. Cross Abhishek N. Prasad Karla A. Fenton Hao Yu Timothy R. Fouts Christopher C. Broder Antony S. Dimitrov |
| author_facet | Thomas W. Geisbert Kathryn Bobb Viktoriya Borisevich Joan B. Geisbert Krystle N. Agans Robert W. Cross Abhishek N. Prasad Karla A. Fenton Hao Yu Timothy R. Fouts Christopher C. Broder Antony S. Dimitrov |
| author_sort | Thomas W. Geisbert |
| collection | DOAJ |
| description | Abstract Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting. |
| first_indexed | 2024-03-11T13:43:16Z |
| format | Article |
| id | doaj.art-652276c0d46b42ed8977b0d8d12fab81 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-11T13:43:16Z |
| publishDate | 2021-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-652276c0d46b42ed8977b0d8d12fab812023-11-02T11:17:51ZengNature Portfolionpj Vaccines2059-01052021-02-016111210.1038/s41541-021-00284-wA single dose investigational subunit vaccine for human use against Nipah virus and Hendra virusThomas W. Geisbert0Kathryn Bobb1Viktoriya Borisevich2Joan B. Geisbert3Krystle N. Agans4Robert W. Cross5Abhishek N. Prasad6Karla A. Fenton7Hao Yu8Timothy R. Fouts9Christopher C. Broder10Antony S. Dimitrov11Galveston National Laboratory, University of Texas Medical BranchProfectus BioSciences, Inc.Galveston National Laboratory, University of Texas Medical BranchGalveston National Laboratory, University of Texas Medical BranchGalveston National Laboratory, University of Texas Medical BranchGalveston National Laboratory, University of Texas Medical BranchGalveston National Laboratory, University of Texas Medical BranchGalveston National Laboratory, University of Texas Medical BranchProfectus BioSciences, Inc.Profectus BioSciences, Inc.Department of Microbiology and Immunology, Uniformed Services UniversityProfectus BioSciences, Inc.Abstract Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.https://doi.org/10.1038/s41541-021-00284-w |
| spellingShingle | Thomas W. Geisbert Kathryn Bobb Viktoriya Borisevich Joan B. Geisbert Krystle N. Agans Robert W. Cross Abhishek N. Prasad Karla A. Fenton Hao Yu Timothy R. Fouts Christopher C. Broder Antony S. Dimitrov A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus npj Vaccines |
| title | A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus |
| title_full | A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus |
| title_fullStr | A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus |
| title_full_unstemmed | A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus |
| title_short | A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus |
| title_sort | single dose investigational subunit vaccine for human use against nipah virus and hendra virus |
| url | https://doi.org/10.1038/s41541-021-00284-w |
| work_keys_str_mv | AT thomaswgeisbert asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT kathrynbobb asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT viktoriyaborisevich asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT joanbgeisbert asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT krystlenagans asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT robertwcross asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT abhisheknprasad asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT karlaafenton asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT haoyu asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT timothyrfouts asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT christophercbroder asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT antonysdimitrov asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT thomaswgeisbert singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT kathrynbobb singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT viktoriyaborisevich singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT joanbgeisbert singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT krystlenagans singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT robertwcross singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT abhisheknprasad singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT karlaafenton singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT haoyu singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT timothyrfouts singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT christophercbroder singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT antonysdimitrov singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus |